Melanoma Education Summit

New Frontiers in Melanoma Management

Presented by the Johns Hopkins University School of Medicine

ACKNOWLEDGEMENT 
Supported by an educational grant from Merck and Co.

TUITION
Complimentary

DATE OF RELEASE/EXPIRATION
Live sessions will be available October 12, 2011 from 9:00 AM-12:00 PM (EST). These presentations will be on-demand from Octoberr 12, 2011 to April 12, 2012 at www.OncologyCareLive.com

ESTIMATED TIME TO COMPLETE
The activity consists of four sessions, which should take approximately 4 hours to complete.

ACTIVITY DIRECTORS 
William Sharfman, MD, Clinical Co-Director of the Melanoma Program at The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins School of Medicine.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live activity: The Johns Hopkins University School of Medicine designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring material: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 3.5 hours of Category 1 credit for completing this program.

JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

INTENDED AUDIENCE
Medical oncologists, radiation oncologists, pulmonologists, and oncology nurses involved in caring for patients with lung cancer, will be targeted as the primary audience for this event. Secondary audiences will include primary care physicians, family physicians, nurses and advanced practice nurses, physician assistants, and pharmacists.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:

  • Identify current approaches to the surgical management of melanoma
  • Discuss the evaluation and development of biomarkers for diagnosis, staging and treatment of melanoma
  • Describe current recommended clinical practice for excision of localized melanomas and patient selection for sentinel lymph node biopsy
  • Identify novel agents and combination systemic therapies of melanoma currently being evaluated in clinical trials
  • Explain current approaches to the surgical management of melanoma

STATEMENT OF NEED
The incidence of melanoma has increased over the last 30 years. Since 1995, there have been rapid annual increases of 3.8% among white women aged 15 to 34 years, and since 2003, increases of 8.8% annually in white men age 65 years or older. Among older Americans, while the death rate has remained stable in women since 1989, it has risen by 3.2% per year since 2002 in the male cohort. While melanoma is highly curable if detected in a localized stage and 80% of melanomas are detected at this stage, regional stage diagnoses realize a 5-10 year survival rate of 60% and distant stage diagnoses offer only a 16% survival rate over the same span. Fortunately, the last two years have added new diagnostic, surgical, and therapeutic possibilities to the armamentarium, and this new information should be widely employed in melanoma treatment.

Surgical options for this initially superficial cancer are straightforward when found in its early stages. However, regional lymph nodes are often involved, and proper surgical management is essential. Sentinel lymph node biopsy (SLNB) combined with lymphatic mapping (LM) has become the standard for accurate staging of melanoma, yet the nuances of execution remain controversial. It has been suggested that if LM/SLNB isn’t performed simultaneously with tumor excision, accuracy is reduced and the risk of undetected micrometastases increases. However, recent investigation has found no difference for outcomes whether SLNB was performed immediately or later, and further large scale research in the same vein should resolve the debate.

Unfortunately, the ideal situation of visual detection of melanoma and deft surgical excision is rarely the case. Molecular methods for both detection and treatment are necessary, yet Ki-67 is the only biomarker assessment routinely used, and standard immunological therapies have limited success. Fortunately, promising work has been done on a number of biomarkers such as MITF, HMB-45, and c-Kit. Gene expression profiling has also yielded diagnostic tools, such as knowledge of CDKN2A BRAF/NRAS and their use in determining prognosis. Newer immunological approaches under investigation include the CTLA-4 blockade, and this work has provided therapeutic options approved for use just this year. And although non-immunologic approaches haven’t provided great success in melanoma treatment, research continues into potential molecular targets, and data for BRAF, Raf/Ras/MAPK, PI3/AKT, tyrosine kinase, poly(ADP Ribose), cMET, and angiogenesis, is promising. This burgeoning variety of treatment approaches has also allowed for combination strategies that afford synergistic treatment effects.

In these last two years, the pace and volume of advances made have far outpaced the ability of the individual practitioner to absorb them into a considered approach to disease treatment. This activity will provide a singular opportunity to address debate and misunderstanding regarding the use of SLNB/LM staging. It will also provide a forum for addressing a lack of familiarity with newer gene profiling and biomarker techniques. Furthermore, this program will address the limited familiarity physicians have with combination therapy approaches to melanoma.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME.  Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity.  Faculty are required to disclose only those relationships that are relevant to their specific presentation.  The following relationships have been reported for this activity:

FACULTY NAME AND LECTURE TITLE(S):

RELATIONSHIP(S):

Paul Chapman, MD
Targeted Therapy and Chemotherapy in Advanced Melanoma

Research Funding: Roche/Genentech, GlaxoSmithKline
Consultant: Roche/Genentech, GlaxoSmithKline
Scientific Advisory Board: Roche/Genentech, GlaxoSmithKline

Leslie Fecher, MD
Targeted Therapy and Chemotherapy in Advanced Melanoma

Research Funding: GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Roche/Genentech
Unpaid Consultant: BMS

Howard Kaufman, MD
Immunotherapy in Patients With High Risk and Advanced Melanoma
Future Directions in Melanoma Therapy–Round Table Discussion

Independent Speaker: Promethius
Consultant: Bristol-Myers Squibb, GlaxoSmithKline, Amgen

William Sharfman, MD
Immunotherapy in Patients With High Risk and Advanced Melanoma
Future Directions in Melanoma Therapy–Round Table Discussion

Panel Member: Merck
Research Funding: GlaxoSmithKline, Novartis
Independent Speaker: Promethius

No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).


PLANNER’S NAME

RELATIONSHIP(S)

William Sharfman, MD

Panel Member: Merck
Research Funding: GlaxoSmithKline, Novartis
Independent Speaker: Promethius


No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products.

FACULTY NAME AND LECTURE TITLE(S)

PRODUCT

Paul Chapman, MD
Targeted Therapy and Chemotherapy in Advanced Melanoma

imatinib, vincristine, paclitaxel, nab-paclitaxel
temozolomide

Donald Morton, MD
Questions in the Surgical Management of Melanoma

PLX 4032, BRAF V600F, BCG, Canvaxin

Howard Kaufman, MD
Immunotherapy in Patients with High Risk Melanoma

Talimogene laherparepvec (Oncovex), MDX-1106

Howard Kaufman, MD
Future Directions in Melanoma Therapy–Round Table Discussion

sipuleucel-T, imatinib

Howard Kaufman, MD
Future Directions in Melanoma Therapy–Round Table Discussion

sipuleucel-T, imatinib

Howard Kaufman, MD
Future Directions in Melanoma Therapy–Round Table Discussion

sipuleucel-T, imatinib

COURSE FORMAT
Live sessions will be 1 hour and will be delivered in the form of video webcasts with real-time Q&A from faculty.

PREREQUISITES
There are no prerequisites.

HARDWARE AND SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion of the post-test, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request

CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES
I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”
For CME Questions, please contact the CME Office
(410) 955-2959 or e-mail cmenet@jhmi.edu.
For CME Certificates, please call (410) 502-9634.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education

Reviewed & Approved by:
Turner 20/720 Rutland Avenue
General Counsel, Johns Hopkins Medicine (4/1/03)
Baltimore, Maryland 21205-2195
Updated 4/09

Lung Cancers Virtual Education Summit

Entering an Era of More Personalized Treatment in Lung Cancer: Increasing Patient Survival Rates

Presented by the Johns Hopkins University School of Medicine

ACKNOWLEDGEMENT
Supported by educational grants from Boehringer Ingelheim, OSI/Astellas and Daiichi Sankyo, Inc.

TUITION
Complimentary

DATE OF RELEASE/EXPIRATION
Live sessions will be available October 12, 2011 from 1:00 PM-6:00 PM (EST). These presentations will be on-demand from October 13, 2011 to April 13, 2012 at www.OncologyCareLive.com

ESTIMATED TIME TO COMPLETE
Each activity will take approximately one hour to complete, for a total of 4.0 hours.

ACTIVITY DIRECTORS
David S. Ettinger, MD, the Alex Grass Professor of Oncology, Johns Hopkins University School of Medicine

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4.0 hours of Category 1 credit for completing this program.

JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

INTENDED AUDIENCE
Medical oncologists, radiation oncologists, pulmonologists, and oncology nurses involved in caring for patients with lung cancer, will be targeted as the primary audience for this event. Secondary audiences will include primary care physicians, family physicians, nurses and advanced practice nurses, physician assistants, and pharmacists.

PREREQUISITES
There are no prerequisites.

STATEMENT OF NEED
Lung cancer remains the greatest cause of cancer mortality in men and women, both in the United States and worldwide, accounting for approximately 25% of all cancer diagnoses and 28% of cancer related mortalities. In 2010 there were approximately 223,000 new cases of lung and bronchial cancer—117,000 among men and 106,000 among women; 157,000 lung and bronchial cancer deaths were expected that year. Even as incidence rates decline in the male population, it continues to rise among women, reflecting historical differences in smoking rates between genders. Lung cancer is classified as either non-small cell lung cancer or small cell lung cancer. NSCLC is much more common than SCLC, constituting 85% of lung cancer cases. Five-year survival rates for lung cancer have remained poor; the 5-year survival rate is 15% for NSCLC and only 5% for all stages of SCLC. Survival rates vary tremendously depending on the stage of disease. For example, patients with stage I NSCLC have a 60% to 80% 5-year survival rate, whereas among those with stage IV disease, the survival rate is less than 5%.4. Historically, diagnostic methods have proven weak both in basic detection ability and influence on prognosis. However, there have been recent, revolutionary breakthroughs in this area in the last year. For example, CT detection techniques have been refined, and with the recent results of long term research, shown to allow early detection that has a measurably positive effect on outcomes. Recent progress with newly validated biomarkers, which can complement and replace imaging techniques, provide tools for classification and treatment considerations as well. These classification techniques enhance the decision process regarding the growing choices of targeted compounds, which further improve outcomes for this historically intractable disease. It has been found that this approach can even rival the benefits obtained with stem cell transplantation. Keeping in mind the historically bleak outlook for lung cancer, recent advances in Medical oncologists, radiation oncologists, pulmonologists, and oncology nurses involved in caring for patients with lung cancer, will be targeted as the primary audience for this event. Secondary audiences will include primary care physicians, family physicians, nurses and advanced practice nurses, physician assistants, and pharmacists. Detection, classification, and treatment, represent new standards of care that should be embraced as rapidly as possible throughout the treatment community. However, clinicians lack knowledge of these advances, and need information about how to incorporate both the new diagnostic tools and standards into their practice. It is hoped that screening of high risk populations will soon become a standard of care through understanding of new data, although there are debates regarding the implementation of this strategy. Furthermore, making precise, individualized treatment decisions through the use of biomarkers and targeted therapy is becoming increasingly possible, but it requires an understanding of the concomitant complexities of this new information to realize the potential of these new possibilities.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:

  • Practice early diagnosis of lung cancer so that patients may be found at less advanced, more treatable stages of the disease.
  • Explain the importance of biomarkers that affect therapeutic efficacy so that patients most likely to benefit from a particular therapy can be identified.
  • Identify targeted therapies available for the treatment of NSCLC and when and how to integrate them in combination with chemotherapy.
  • Discuss current research data on treatment options for patients with SCLC.

COURSE FORMAT
Live sessions are approximately one hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.OncologyCareLive.com

PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request.

HIPAA STATEMENT


CONFIDENTIALITY DISCLAIMER FOR CME CONFERENCE ATTENDEES

I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office at (410) 955-2959 or e-mail cmenet@jhmi.edu.
For CME Certificates, please call (410) 502-9634.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195

Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)
Updated 4/09

Lymphoid Leukemia Education Summit

Conversations and Controversies in Hematologic Malignancies and Hematology

Presented by the Johns Hopkins University School of Medicine.

ACKNOWLEDGEMENT 
Supported by an educational grant from Millennium: The Takeda Oncology Company

TUITION
Complimentary

DATE OF RELEASE/EXPIRATION
Live sessions will be available September 7, 2011 from 12:30 PM-6:00 PM (EST). These presentations will be on-demand from September 8, 2011 to March 8, 2012 at www.OncologyCareLive.com

ESTIMATED TIME TO COMPLETE
The activity consists of five sessions, which should take approximately 4.5 hours to complete.

ACTIVITY DIRECTORS 
Carol Ann Huff, MD, Associate Professor of Oncology, Assistant Professor of Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, and Judith E. Karp, MD, Professor of Oncology and Medicine, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live activity: The Johns Hopkins University School of Medicine designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring material: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 4.5 hours of Category 1 credit for completing this program.

JOHNS HOPKINS STATEMENT OF RESPOSIBILITY
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

INTENDED AUDIENCE 
Hematologists, hematologists/oncologists, medical oncologists, pathologists, oncology nurses, advanced practice nurses, pharmacists, and other healthcare professionals who care for lymphoid leukemia patients.

PREREQUISITES
There are no prerequisites.

STATEMENT OF NEED 
Lymphoid leukemias are characterized by the proliferation and enlargement of lymphoid tissue in various sites and by increased numbers of lymphocytic cells in the blood and in various tissues and organs. Chronic lymphocytic leukemia (CLL) is the most common of these disorders, and nearly 15,000 new cases and 4,400 deaths were reported in 2010. CLL is more common in Caucasians than African Americans, and the median age at diagnosis is 60 to 68 years. Acute lymphocytic leukemia (ALL) is the most common type of leukemia in children aged less than 20 years; however, adults may develop ALL as well, and its incidence in this group increases in those 45 years of age and older. ALL accounted for 5,300 cases and 1,400 deaths in 2010. While most pediatric patients are cured of their disease, the majority of adults are not, and many die of ALL.

Prognosis for all patients with relapsed or refractory ALL disease is poor. Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of disorders involving malignant proliferation of lymphoid cells in lymphoreticular sites including lymph nodes, bone marrow, the spleen, the liver, and the GI tract. NHL is the 5th most frequently diagnosed malignancy in the United States. Estimates indicate that more than 66,000 cases of NHL were diagnosed in 2008. Multiple myeloma (MM) accounts for about 1% of all malignancies and about 10% of hematologic malignancies. An estimated 20,180 new cases of MM were diagnosed in the U.S. in 2010, with more cases in men than in women. About 10,650 persons in this country were expected to die of MM in 2010. In spite of recent advances in the treatment of MM, including the introduction of stem cell transplantation and newer therapies into clinical practice, the disease remains incurable and uniformly fatal.

Identified Practice Gaps in Lymphoid Leukemia Management: 1. Inadequate understanding of the optimal treatment approach for individual patients with lymphoid leukemia; 2. Limited knowledge of the role of stem cell transplantation and the identification of suitable candidates; 3. Lack of familiarity with the role of disease biomarkers and genetic profiling; 4. Inadequate knowledge of the optimal approach to the management of skeletal, renal, and other leukemia complications; and 5. Lack of familiarity with the unique management needs of clinically important patient subgroups including the elderly and those with asymptomatic disease, refractory disease, and relapse following stem cell transplantation.

The need for this educational activity has been established according to ACCME standards by expert assessment of a wide range of sources, including in-depth review of relevant medical literature, analysis of available quality of care and practice gap studies, and expert opinion as reflected in the faculty members' choices of topics and content (see attachment 4: previous course evaluation). The resulting educational activity will include fair and balanced information on relevant therapies, including efficacy and a discussion of adverse events if warranted. It will make use of clinical data that is as up-to-date as possible, including clinical trial results recently presented at major U.S. meetings, such as the American Society of Clinical Oncology Annual Meeting (ASCO), the American Society of Hematology (ASH) annual meeting, the National Comprehensive Cancer Network (NCCN) Annual Summit and international meetings including the European Society for Medical Oncology (ESMO) annual meeting. Important regional meetings will also be included. Content will include clinical data recently published in major peer-reviewed journals and input from acknowledged experts and clinicians experienced in the field of lymphoid leukemia.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:

  • Explain the role of newer agents in the treatment of patients with lymphoid leukemia
  • Explain the role of autologous transplantation in multiple myeloma in 2011
  • Formulate patient management strategies using a risk-adapted approach to the treatment of lymphoid leukemia
  • Identify optimal treatment approaches for patients with high risk multiple myeloma
  • Discuss the unique management needs of clinically important patient subgroups including those with asymptomatic, advanced, and refractory malignancies
  • Identify patient- and disease-associated factors that impact the choice of therapeutic agents
  • Discuss the state of cancer care

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME.  Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity.  Faculty are required to disclose only those relationships that are relevant to their specific presentation.  The following relationships have been reported for this activity:

PLANNER’S NAME AND LECTURE TITLE(S):

RELATIONSHIP(S):

Carl Ann Huff, MD
Perspectives in Multiple Myeloma:Transplantation, Maintenance Therapy and Optimal Initial Treatment Regimen

Research funding: Geron, Bristol Myers Squibb

Honorarium: Onyx Pharmaceuticals, Amgen, Bristol Myers Squibb

Jack Goldberg, MD
CCL – Treatment of High-Risk Disease
in a Young Patient

Speakers Bureau: Genentech, Cephalon, Millenium
(all inactive since 1/2011)

Myron Czuczman, MD
New Agents in NHL: Where Do They Fit
in the Treatment Paradigm?

Advisor: Genentech, GlaxoSmithKline

Research Funding: Genmab, Celgene

Honorarium: Celgene, Cephalon, GlaxoSmithKline, Millenium

Wendy Stock, MD
Debate: ALL in Adolescents and Young Adults – is it a Different Disease?

Research Funding: Sigma Tau

Stephen Hunger, MD
Debate: ALL in Adolescents and Young Adults – is it a Different Disease?

Advisor, Stock Ownership: Bristol Myers Squibb

No other faculty members have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

PLANNER’S NAME

RELATIONSHIP(S)

Carol Ann Huff, MD

Research funding: Geron, Bristol Myers Squibb

Honorarium: Onyx Pharmaceuticals, Amgen, Bristol Myers Squibb


No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

NAME AND LECTURE TITLE(S)

PRODUCT(S):

Vincent Rajkumar, MD
Perspectives in Multiple Myeloma: Transplantation, Maintenance Therapy
and Optimal Initial Treatment Regimen

lenalidomide, Vorinostat, Carfilzomib, Panabinostat, elotuzumab

Carl Ann Huff, MD
Perspectives in Multiple Myeloma: Transplantation, Maintenance Therapy
and Optimal Initial Treatment Regimen

lenalicomide, bortezomib

Aaron Rapoport, MD
New Agents in NHL: Where Do They
Fit in the Treatment Paradigm?

veltuzamab, blinatumomab (MT103), inotuzumab

Ron Gartenhaus, MD
New Agents in NHL: Where Do They
Fit in the Treatment Paradigm?

veltuzamab, blinatumomab (MT103), inotuzumab

Myron Czuczman, MD
New Agents in NHL: Where Do They
Fit in the Treatment Paradigm?

veltuzamab, blinatumomab (MT103), inotuzumab

COURSE FORMAT
Live sessions will be either 30 minutes or 1 hour and will be delivered in the form of video webcasts with real-time Q&A from faculty at www.CardioCareLive.com

PRE AND POST TEST AND EVALUATION
Prior to and immediately after each presentation, participants will be presented with a series of multiple choice test questions. After each presentation participants will also be presented with an online activity evaluation. A CME certificate of credit will be issued upon successful completion of the post-test, which includes a passing grade of 70% or more. Participants must document the amount of time they spent in the activity.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine's CME program. CME collects only the information necessary to provide you with the services that you request

Register Now

Forgot Password
Click Here To Login